FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> NM100060 | Nexmed | Novartis

Novartis decision hurts NexMed shares

Tools

Novartis will not submit a new drug application for NexMed's topical experimental treatment for nail fungus, and that decision is hurting NexMed's share prices. The drug developer saw shares drop several times throughout the day yesterday. According to Novartis, late stage clinical trials on the treatment, called NM100060, were the cause of the decision. The topical treatment is aimed at mild to moderate toenail fungus.

In 2005, Novartis took on all regulatory, manufacturing, commercialization and clinical development responsibilities for the treatment in an exclusive, worldwide $4 million licensing deal, which had potential to net NexMed up to $47 million.

NexMed is hoping to recover following a mid-2009 release of the results of a comparator study in Europe, according to the company's president and chief executive officer, Vivian Lu.

- see NexMed's release
- read the story at CNN Money
- find out more at Market Watch

Related Articles:
NexMed ED therapy draws a "non-approvable" letter
NexMed - Best Pharma Stocks of 2007
NexMed taps Berman as new CEO

More stories about NM100060   Nexmed   Novartis  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 27 + 49?
To combat spam, please solve the math question above.